| P50 | author | Paweł Kawalec | Q95945656 |
| | Andrzej Pilc | Q43012502 |
| P2093 | author name string | Alicja Mikrut | |
| | Natalia Wiśniewska | |
| P2860 | cites work | Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis | Q21134808 |
| | 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis | Q26828418 |
| | Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. | Q51866375 |
| | A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response | Q57169478 |
| | Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis | Q58912330 |
| | A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone | Q82066071 |
| | Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate | Q84127900 |
| | Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis | Q84675149 |
| | Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis | Q84751886 |
| | Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs | Q85001070 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 |
| | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment | Q33668201 |
| | Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes | Q34132778 |
| | Tofacitinib for the treatment of rheumatoid arthritis | Q34275878 |
| | Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 | Q34523450 |
| | Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study | Q34561675 |
| | Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis | Q34677487 |
| | The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 |
| | A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. | Q37601368 |
| | JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical | Q38065100 |
| | A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis | Q38097494 |
| | Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial | Q45842857 |
| | American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.0 Generic | Q44128984 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| | rheumatoid arthritis | Q187255 |
| | heterocyclic compound | Q193430 |
| | meta-analysis | Q815382 |
| | systematic review | Q1504425 |
| | mechanism of action | Q3271540 |
| | pyrrole | Q67954132 |
| | pyrimidine | Q47069735 |
| P304 | page(s) | 1415-1424 | |
| P577 | publication date | 2013-07-23 | |
| | 2013-10-01 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis | |
| P478 | volume | 32 | |